0RD1
vs
O
OMX Stockholm 30
0RD1
Over the past 12 months, 0RD1 has underperformed OMX Stockholm 30, delivering a return of -8% compared to the OMX Stockholm 30's +33% growth.
Stocks Performance
0RD1 vs OMX Stockholm 30
Performance Gap
0RD1 vs OMX Stockholm 30
Performance By Year
0RD1 vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Camurus AB
Glance View
Camurus AB is a Swedish pharmaceutical company that stands out in the industry with its innovative approach to treating chronic and rare diseases. Rooted in its proprietary FluidCrystal® injection depot technology, Camurus integrates this platform into the development of long-acting medications that aim to improve patient compliance and outcomes. This lipid-based system allows for the extended release of active substances, providing sustained therapeutic effects from just a single dose. Founded in 1991, the company has strategically focused its efforts on areas often underserved by traditional pharmaceutical giants, such as addiction, pain management, and endocrine disorders. By concentrating on these specific therapeutic areas, Camurus not only addresses significant health challenges but also carves out a niche with limited competition, potentially leading to substantial revenue streams. The company generates its income predominantly through product sales and strategic partnerships. One of its flagship products is Buvidal®, a long-acting medication for the treatment of opioid dependence, which has made significant inroads across Europe and Australia. The sustained revenue from Buvidal® highlights the company's adeptness at capitalizing on its technology to create tangible healthcare solutions. Additionally, Camurus engages in licensing agreements and collaborations with international pharmaceutical firms, expanding its market reach and leveraging its technology across a broader canvas. By investing heavily in research and development, Camurus ensures its pipeline continues to be robust, with new products consistently in various stages of clinical trials, thereby securing its financial performance and position in the pharmaceutical industry.
